Q4 2024 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) reported its 7th consecutive quarter of revenue and adjusted EBITDA growth, showcasing strong operational execution.
- The company achieved a 4% increase in revenues on a reported basis and 7% on an organic basis for the fourth quarter of 2024, excluding Bausch & Lomb.
- BHC generated approximately $1.3 billion in adjusted operating cash flow for the full year, exceeding guidance.
- The company made significant progress in its strategic priorities, including innovation and efficiency, with the approval of Thermage FLX in China and the use of AI in sales processes.
- BHC reduced its net debt by almost a billion dollars in 2024, strengthening its financial position and capital structure.
- The international segment saw a 4% decrease in reported revenues for the fourth quarter, impacted by currency fluctuations, particularly the strengthening of the dollar against the Mexican peso.
- The diversified segment experienced a 12% decrease in revenues due to the absence of a prior year's generic supply shortage that boosted sales.
- Bausch Health Companies Inc (BHC) faces potential challenges with the FDA lawsuit regarding Norwich's ANDA and the potential impact on Zifaxan's market exclusivity.
- The company anticipates a reduction in adjusted cash flow from operations in 2025 due to the absence of one-time benefits experienced in 2024.
- BHC's exploration of selling Bausch & Lomb did not result in an offer reflecting its long-term value, indicating potential difficulties in monetizing this asset.
Welcome to the Bosch Health 4th quarter 2024 earnings call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation.
Please note this conference is being recorded.
I will now turn the conference over to your host, Garin Saraian Investor Relations of Bosch. You may begin.
Good afternoon and welcome to Busch's 4th quarter 2024 earnings conference call. Participating in today's call are Thomas Apio, Chief Executive Officer of Baosha, and JJ Sharon, Chief Financial Officer.
Before we begin, I'd like to remind you that our presentation today contains forward-looking information.
We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the slides that accompany this presentation, as it contains important information.
Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
